📊 ZBIO Key Takeaways
Is Zenas BioPharma, Inc. (ZBIO) a Good Investment?
Zenas BioPharma exhibits severe financial distress with $10M in revenue against $383M in operating losses, representing a fundamentally unsustainable business model. Annual cash burn of $172.4M against $110.6M in available cash creates an 7-8 month runway, necessitating imminent capital raises that will significantly dilute shareholders. While adequate balance sheet liquidity and low leverage provide near-term survival capability, accelerating losses (-140.6% YoY) indicate deteriorating operational efficiency and fundamental product/revenue challenges.
Why Buy Zenas BioPharma, Inc. Stock? ZBIO Key Strengths
- Strong liquidity position with 5.61x current ratio providing runway for operations
- Manageable debt burden with 0.32x debt-to-equity ratio limiting bankruptcy risk
- EPS improved 29% YoY, indicating losses are contracting in relative terms
ZBIO Stock Risks: Zenas BioPharma, Inc. Investment Risks
- Catastrophic cash burn of $172.4M annually with only $110.6M cash reserves (7-8 month runway)
- Revenue growth flat at 0% YoY with losses of $37.77 per dollar of revenue, indicating pre-commercial stage with severe profitability challenges
- Net losses accelerated 140.6% YoY, demonstrating deteriorating operational performance and rising cash consumption
- Imminent need for dilutive capital raises or strategic alternatives (acquisition/merger) to continue operations
Key Metrics to Watch
- Quarterly cash burn rate trend and remaining cash runway
- Revenue growth trajectory and path to positive gross margins
- Capital raise announcements and dilution impact
- Clinical development milestones and regulatory progress
- Operating expense reduction initiatives
Zenas BioPharma, Inc. (ZBIO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.61x current ratio provides a solid financial cushion.
ZBIO Profit Margin, ROE & Profitability Analysis
ZBIO vs Healthcare Sector: How Zenas BioPharma, Inc. Compares
How Zenas BioPharma, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Zenas BioPharma, Inc. Stock Overvalued? ZBIO Valuation Analysis 2026
Based on fundamental analysis, Zenas BioPharma, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Zenas BioPharma, Inc. Balance Sheet: ZBIO Debt, Cash & Liquidity
ZBIO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Zenas BioPharma, Inc.'s revenue has declined by 80% over the 5-year period, indicating business contraction. The most recent EPS of $-11.89 indicates the company is currently unprofitable.
ZBIO Revenue Growth, EPS Growth & YoY Performance
ZBIO Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $10.0M | -$27.8M | $-1.22 |
| Q2 2025 | $10.0M | -$27.8M | $-1.25 |
| Q1 2025 | $10.0M | -$27.8M | $-0.80 |
| Q3 2024 | $50.0M | -$12.5M | $1.96 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Zenas BioPharma, Inc. Dividends, Buybacks & Capital Allocation
ZBIO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Zenas BioPharma, Inc. (CIK: 0001953926)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ZBIO
What is the AI rating for ZBIO?
Zenas BioPharma, Inc. (ZBIO) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ZBIO's key strengths?
Claude: Strong liquidity position with 5.61x current ratio providing runway for operations. Manageable debt burden with 0.32x debt-to-equity ratio limiting bankruptcy risk.
What are the risks of investing in ZBIO?
Claude: Catastrophic cash burn of $172.4M annually with only $110.6M cash reserves (7-8 month runway). Revenue growth flat at 0% YoY with losses of $37.77 per dollar of revenue, indicating pre-commercial stage with severe profitability challenges.
What is ZBIO's revenue and growth?
Zenas BioPharma, Inc. reported revenue of $10.0M.
Does ZBIO pay dividends?
Zenas BioPharma, Inc. does not currently pay dividends.
Where can I find ZBIO SEC filings?
Official SEC filings for Zenas BioPharma, Inc. (CIK: 0001953926) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ZBIO's EPS?
Zenas BioPharma, Inc. has a diluted EPS of $-8.44.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ZBIO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Zenas BioPharma, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ZBIO stock overvalued or undervalued?
Valuation metrics for ZBIO: ROE of -156.0% (sector avg: 15%), net margin of -3,777.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ZBIO stock in 2026?
Our dual AI analysis gives Zenas BioPharma, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ZBIO's free cash flow?
Zenas BioPharma, Inc.'s operating cash flow is $-172.3M, with capital expenditures of $18.0K. FCF margin is -1,723.5%.
How does ZBIO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,777.4% (avg: 12%), ROE -156.0% (avg: 15%), current ratio 5.61 (avg: 2).